Aurigene Discovery Technologies Limited

Aurigene Discovery Technologies Limited is a biotechnology company focused on oncology and inflammatory diseases. It develops therapies for the treatment of oncology and inflammatory diseases. The company has a range of programs in the fields of immunomodulation (immune checkpoint pathways), epigenetics (EZH2), and Th17 pathways (RoR gamma, IRAK4), spanning from early optimization to IND stage. It has also developed CA-170, an orally available small molecule targeting the immune checkpoints PDL1 and VISTA. Additionally, the company offers collaborative services for integrated peptide discovery programs as well as FTE and FFS services for peptide synthesis, including scale-up to gram quantities.